Showing posts with label Cardiovascular. Show all posts
Showing posts with label Cardiovascular. Show all posts

ReportsandReports - The Cardiovascular Market Outlook to 2014: Competitive landscape, global market analysis and pipeline analysis



The Cardiovascular Market Outlook to 2014 provides comprehensive coverage of the cardiovascular market, incorporating a disease overview and detailed epidemiological analyses of the major indications. This report makes a wide-ranging assessment of the marketed product portfolio, R&D pipeline, market share data, sales forecast and competitive landscape for the major players. Furthermore, it highlights the key market and R&D trends that may influence treatment sales; with a thorough analysis of the competitive dynamics of leading brands within each indication, in order to enable the reader to identify growth brands, key drug classes and leading players through 2014.

The cardiovascular market may be segmented into numerous subcategories, including antihypertensives, antidyslipidemics, antithrombotics, cardiac therapies and other cardiovascular agents. While established treatments are currently available for each of these therapeutic subcategories, these markets are large and significant unmet medical needs still exists. Among the various cardiovascular indications, dyslipidemia had the highest prevalence in 2008, with over 300m people affected by the condition.

The global cardiovascular market is quite dynamic and has remained a leading therapy area in the global pharmaceutical market. Although the seven major markets (7MM) have captured a significant market share of the global cardiovascular market sales, these countries have recorded a strong Y-o-Y decline in 2008. The US continued to be a dominant market but registered a Y-o-Y decline in 2008, which was mainly attributed to increasing generic presence and market maturity in several key therapeutic categories.

Key features of this report
  • Epidemiological analysis and forecast prevalence of the major cardiovascular indications such as hypertension, dyslipidemia and stroke over the period 2008–14.
  • Forecasts and analysis of the major products in the cardiovascular market over the period 2008-14 spread across the major indications and classes of treatments.
  • Overview of key events in the global cardiovascular market that have impacted treatment trends and sales potential across the major cardiovascular indications.
  • Strategic and growth analysis of leading pharmaceutical corporations based on sales focus by drug class, currently marketed products and R&D product portfolios.
Scope of this report
  • Quantify patient potential, assess treatment trends and sales patterns across the major cardiovascular disorder indications in the US, Japan and top 5 EU markets.
  • Discover which indications have the greatest potential to provide franchise growth and understand the growth drivers of the major classes such as antihypertensives, antidyslipidemics, antithrombotics, cardiac therapies and other cardiovascular agents.
  • Compare the franchises of top pharmaceutical marketers across major indications, and evaluate how market share of leading companies, such as Pfizer, Sanofi-Aventis, Novartis, Merck, BMS and AstraZeneca will change over the next 5 years.
  • Quick and comprehensive understanding of how recent events are affecting the performance of major products, and how leading players are confronting competitive challenges in the cardiovascular marketplace.
Key questions answered
  • What will be the major growth indications and the accompanying growth drivers in the cardiovascular arena over the period 2008–14?
  • What are the current trends within the major therapy areas such as antihypertensives, antidyslipidemics, antithrombotics, cardiac therapies and other cardiovascular agents across the seven major markets?
  • How have recent launches from companies such as Pfizer, Sanofi-Aventis, Novartis, Merck, BMS and AstraZeneca performed in the market place?
  • What are the most promising compounds currently in clinical development for major cardiovascular indications, and what is the forecast commercial potential of these products through 2014?
About Us

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004

Read More
Posted by Unknown on
categories: , , , , , , , |

ReportsandReports - The Cardiovascular Market Outlook to 2015: Competitive landscape, global market analysis, key trends and pipeline analysis



The Cardiovascular Market Outlook to 2015 provides comprehensive coverage of the cardiovascular market, incorporating a disease overview and detailed epidemiological analyses of the major indications. This report makes a wide-ranging assessment of the marketed product portfolio, R&D pipeline, market share data, sales forecast and competitive landscape for the major players. 

Furthermore, it highlights the key market and R&D trends that may influence treatment sales; with a thorough analysis of the competitive dynamics of leading brands within each indication, in order to enable the reader to identify growing brands, key drug classes and leading players through 2015.
The cardiovascular market may be segmented into numerous subcategories, including antihypertensives, antidyslipidemics, antithrombotics, cardiac therapies and other cardiovascular agents. While established treatments are currently available for each of these therapeutic subcategories, these markets are large and significant unmet medical needs still exists. Among the various cardiovascular indications, dyslipidemia had the highest prevalence in 2009, with approximately 333m people affected by the condition.

The global cardiovascular market is quite dynamic and has remained a leading therapy area in the global pharmaceutical market. The seven major markets (7MM) captured a significant market share of the global cardiovascular market and also recorded a moderate Y-o-Y growth in 2009. The US continued to be a dominant market and registered a Y-o-Y increase in 2009, mainly attributed to the performance of key categories such as statins and beta blockers.

In terms of pipeline developments, the thrombosis market has witnessed a lot of activity, with promising new drugs such as Sanofi-Aventis’ Multaq (launched in the US in 2009), J&J/Bayer’s Xarelto (launched in 2008), Pfizer/BMS’s apixaban (under registration), Eli Lilly/Daiichi Sankyo’s Effient (approved in 2009) and Boehringer Ingelheim’s Pradaxa (launched in 2008). These oral drugs are expected to widen the thrombosis market significantly, while also extending the prescription period. Additionally, these new generation drugs are set to undermine Lovenox’s (Sanofi-Aventis) monopoly in the thrombosis market.

Key features of this report
  • Epidemiological analysis and forecast prevalence of the major cardiovascular indications such as hypertension, dyslipidemia and stroke over the period 2009–15.
  • Forecasts and analysis of the major products in the cardiovascular market over the period 2009-15 spread across the major indications and classes of treatments.
  • Overview of key events in the global cardiovascular market that have impacted treatment trends and sales potential across the major cardiovascular indications.
  • Strategic and growth analysis of leading pharmaceutical corporations based on sales focus by drug class, currently marketed products and R&D product portfolios.
  • Detailed analysis across major classes of cardiovascular treatments including antihypertensives, antidyslipidemics, antithrombotics, cardiac therapies and other cardiovascular agents.
Scope of this report
  • Quantify patient potential, assess treatment trends and sales patterns across the major cardiovascular disorder indications in the US, Japan and top 5 EU markets.
  • Discover which indications have the greatest potential to provide franchise growth and understand the growth drivers of the major classes such as antihypertensives, antidyslipidemics, antithrombotics, cardiac therapies and other cardiovascular agents.
  • Compare the franchises of top pharmaceutical marketers across major indications, and evaluate how market share of leading companies, such as Pfizer, Sanofi-Aventis, Novartis, Merck, AstraZeneca and BMS will change over the next 5 years.
  • Quick and comprehensive understanding of how recent events are affecting the performance of major products, and how leading players are confronting competitive challenges in the cardiovascular marketplace.
  • Gain up-to-date competitive intelligence across the cardiovascular portfolio and understand the major issues affecting key pharmaceutical marketers and product development.
Key Market Issues
  • Angiotensin receptor blockers may cause increased cancer risk: In June 2010, the Lancet Oncololgy journal published a meta-analysis study which indicated that ARBs (angtiotensin receptor blockers) have an increased cancer risk. The study involved 61,590 patients from five clinical trials and the results demonstrated that ARBs increased the relative risk of new cancer occurrence by 7.2% versus 6% in control groups
  • Crestor’s patent upheld in the US: AstraZeneca’s blockbuster antidyslipidemic Crestor, the biggest growth driver within cholesterol lowering drugs received a boost after its patent was upheld by a US district court in June 2010, following a four month trial which began in February same year. Crestor is currently the only branded statin in the US market which is witnessing positive growth and this judgement is expected to improve its prospects through the forecast period.
  • Plavix boxed warning for poor metabolizers: Sanofi-Aventis’/BMS’ Plavix, received a boxed warning to its US label in March 2010, indicating a warning about the diminished effectiveness of the drug in patients with a variant of the CYP2C1P liver enzyme leading to reduced formation of the active metabolite. Sanofi-Aventis conducted a study in 40 subjects, with 10 each in the four metabolizer types and found that the poor metabolizers had notably lower levels of Plavix and anti-platelets. This patient pool termed as poor metabolizers includes approximately 14% of Chinese, 4% of blacks and 2% of caucasians.
  • Apixaban’s Phase III AVERROES trial halted: In June 2010, BMS halted its Phase III AVERROES trial in vitamin K antagonist intolerant patients with atrial fibrillation. Interim data from the trial revealed that the drug reduced stroke and systemic embolism in comparison with aspirin, in addition to demonstrating sufficient safety prompting the company to take this decision. Apixaban has already been filed in the EU for prevention of VTE in adults who are undergoing elective hip or knee replacement therapies.
Key findings from this report
  • The global cardiovascular market was valued over $120bn in sales in 2009. The US continued to be the single largest market which was mainly attributed to increasing generic presence and market maturity in several key therapeutic categories. However, Business Insights anticipates the market to decline through 2015 due to the impending patent expiries of several leading drugs.
  • Antihypertensives remained the largest selling therapeutic sub-category in 2009 led by Novartis’s Diovan. Pfizer’s Norvasc, which was the leading antihypertensive till 2007, has been noting a steady decline and losing market share to Diovan since 2008.
  • ARBs continued to be the most prescribed antihypertensives in 2009 although their sales are likely to be clipped by the appearance of Cozaar generics in 2010. ACE inhibitors have been declining due to genericization and competition from ARBs such as the Diovan franchise and Blopress.
  • Antidyslipidemics formed the second largest segment of the cardiovascular market in 2009. This category was dominated by statins with only a small presence of other drug classes.
Key questions answered
  • What will be the major growth indications and the accompanying growth drivers in the cardiovascular arena over the period 2009–15?
  • What are the current trends within the major therapy areas such as antihypertensives, antidyslipidemics, antithrombotics, cardiac therapies and other cardiovascular agents across the seven major markets, and Brazil, Russia, India and China (BRIC)?
  • How have recent launches from companies such as Pfizer, Sanofi-Aventis, Novartis, Merck, AstraZeneca and BMS performed in the market place?
  • What are the most promising compounds currently in clinical development for major cardiovascular indications, and what is the forecast commercial potential of these products through 2015?
About Us

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser’s URL address field. Remove the space if one exists.)

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004

Read More
Posted by Unknown on
categories: , , , , , , , |

ReportsandReports - The Top 10 Cardiovascular Device Companies: Market trends, growth strategies, and SWOT analyses



The cardiovascular (CV) device industry is highly competitive and has reached maturity resulting in single digit growth rates of prominent devices such as pacemakers, defibrillators, and drug eluting stents (DES). Innovations in niche sectors such as atrial fibrillation (AF) and ventricular assist devices (VADs) are poised for double digit growth in the near to mid-term future. From 2007–09, the top three companies in the CV segment acquired other smaller firms to expand their product portfolios and to gain market share in new geographies. Some major companies also established manufacturing facilities outside the US to enhance cost containment and product distribution. The CV device market remained relatively resilient during the economic downturn compared with other healthcare segments. The 2007–09 period also witnessed a considerable rise in consolidation activities among major companies.
This report provides detailed profiles of the top 10 cardiovascular (CV) device companies and brief profiles of other major players. It also elucidates trends within the cardiovascular device market. The detailed profiles contain descriptions of business, financial performance, growth strategies and SWOT analyses.

The analysis is based on:
  • Each company’s consolidated and segmental financial performance;
  • Each company’s growth strategies and major acquisitions and divestments relating to the CV devices market;
  • Key partnerships and alliances formed by these companies;
  • Business-related strengths and weaknesses of these companies and insights into the opportunities and threats facing them.
Key features of this report
Drivers
  • Innovations in CRM and DES segments such as MRI compatible pacemakers from Medtronic and Abbott’s Xience drug eluting stent with their positive clinical outcomes support stronger evidence for long-term benefits.
  • Emerging markets for DES in Canada, China and parts of Asia furnish opportunities to expand businesses for CV companies.
  • Ageing population in industrialized markets such as the US, Europe and Japan are increasing. Moreover, the ICDs and pacemakers in these geographies are expected to have a second-phase of CRM implants.
Resistors
  • The safety and efficacy of DES are under scrutiny following numerous clinical studies and more studies are being executed to justify the long-term efficacy of DES intervention.
  • Markets for ICDs and pacemakers have reached maturation. ICD sales are growing between 4-5% and pacemakers between 2-3% annually.
  • Reduction in reimbursement affects sales and profitability for CV device manufacturers.
Scope of this report
  • Learn from the business operation strategies of the premier CV device companies to target future growth markets effectively, avoid their mistakes, and replicate their successes.
  • Benchmark your performance against the leading CV device companies.
  • Analyze the growth strategies of major players in the CV industry and how their business models are planned for the next 3 to 5 years.
  • Compare performances of the top 10 companies in the CV market with respect to acquisitions, new product innovation, geographic expansion, and industry challenges.
  • Save time, money and resources on analyzing the performance of leading CV device companies using this report.
Key Market Issues

Pricing pressures due to industry regulations

The CV device industry is highly regulated around the world with stringent guidelines defined by regulatory bodies. The medical device approvals by governing bodies such as the FDA in the US have become very meticulous that CV device manufacturers are launching products outside the US such as Europe and Canada. Since the prices are strictly regulated outside the US, manufacturers will be forced to launch their products in the US for a similar price. In the long run, the pricing pressures would continue to prevail and limit the profitability margins for CV device manufacturers.

Significance of CV device innovation

Markets reaching saturation for major revenue generators in the CV device segment such as ICD, pacemaker and DES. New device innovation will be the only parameter that will assure a company of its competitive edge. Novel technologies that are uncontested would help a company by allowing it to charge premium pricing. Research & development (R&D) initiatives and interdisciplinary knowledge will remain the benchmark for assuring a company’s success and commanding prevalence in the market.
Decline in capital expenditure of hospitals

In the US, hospitals spend a considerable amount of their revenues on capital expenditure to improve their facilities and purchase new medical technology. However, the impact of economic recession since 2008 had forced hospitals to decrease their capital expenditure by almost 6%. This decline will impact the medical devices industry across all sectors in the CV device division. Some segments of the CV device industry such as ICD, pacemakers, heart valves and stents will remain insulated from the economic impact given their non-elective nature of associated procedures. other low budget, high-frequency CV accessories that hospitals purchases on a regular basis will be affected due to decline of capital expenditures.

Key findings from this report
  • The top 10 companies had cumulative revenues of $27bn in 2009 and over 95% share of the global CV device market. The top 3 CV device companies dominate more than 60% of this segment’s market share.
  • Medtronic was the No. 1 company with CV device revenues of $8.6bn in 2009. The company strategically acquired other franchises to expand its heart valve and catheter product portfolios.
  • The growth rates of the implantable cardioverter defibrillator (ICD) and pacemaker sectors in 2009 were 4–5% and 2–3% respectively. The ventricular assist device (VAD) and atrial fibrillation (AF) sectors are poised for double-digit growth rates over the next 2–3 years.
  • Business Insights’ analysis revealed that, even during economic recession, the CV device market has remained buoyant, achieving single-digit growth. However, the growth rate in this segment – with the exception of AF solutions and VAD sales – will remain in the mid single digits over the next decade.
Key questions answered
  • What was the market value of the global CV device industry in 2009?
  • What are the global market values for the major CV device segments?
  • What are the key trends in the CV device industry and what are the leading companies’ strategic responses?
  • Who are the major players in the global CV device market?
  • What are the growth strategies of the leading CV device companies?
About Us

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser’s URL address field. Remove the space if one exists.)

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004

Read More
Posted by Unknown on
categories: , , , , , , , , |